Vice President, Global Head of Strategic Regimens
Position Overview: VP, Global Head of Strategic Regimens
The VP, Global Head of Strategic Regimens at AstraZeneca is a pivotal leadership role focused on the implementation and integration of the company's strategy and portfolio activities on a global scale. This position is integral to establishing AstraZeneca's strategic direction, organizational structure, and capabilities for both the commercial and scientific research portfolios. A critical responsibility of this role includes overseeing the project planning process.
As AstraZeneca's Oncology R&D portfolio expands, encompassing a wide range of assets and modalities with overlapping tumor indications, the VP, Global Head of Strategic Regimens will be charged with the strategic development of novel regimens and the lifecycle management of AstraZeneca's assets. The role aims to transform and innovate the current portfolio, continually pioneering new domains.
Key responsibilities include focusing on Phase 3 data generation by translating scientific insights for novel combinations, considering regulatory aspects to streamline pivotal studies, and creating value by identifying strategic opportunities. The position demands a profound understanding of specific tumor areas and the ability to collaborate effectively with late-stage development, regulatory sciences, early global development teams, tumor councils, and the oncology business unit. An understanding of platforms of other comparative studies designs as a delivery mechanism for Phase 3 enabling data is crucial. The role is part of the Early Global Projects Team within the Early Oncology Organization in Oncology R&D and reports to the VP of Global Projects.
Job Specification
Accountable for generating safety/PoC data for novel regimens in various cancer indications through the development of platform clinical studies to support life cycle management strategy of AZ’s emerging portfolio.
Responsible for creating enduring strategy for ongoing linkage between early and late stage Onc R&D teams to develop novel regimens with transformational potential and to maximize value of each asset.
Responsible for partnering at the most senior levels with late-stage development, regulatory sciences, early global development teams, tumor councils, and the oncology business unit.
Builds teams that develop global Ph2 platform studies to support AZ assets in tumor indications with high unmet clinical need aligned with overall AZ vision and strategy.
Responsible for development of platform study design, budget, timeline and delivery of data to support Ph3 investment decisions.
Develops, mentors, and leads a group of GPLs with experience in clinical delivery of early phase studies with tumor specific focused backgrounds in various tumor types.
Required Experience:
MD/PhD or both, with 15+ years of experience in industry.
Deep understanding of Oncology drug development, including platform studies, master protocols, etc.
Broad understanding of the evolving clinical and regulatory landscape in oncology
Demonstrated experience leading and motivating teams in a highly matrixed environment.
Proven record of cultivating and managing internal and external cross-functional collaborations.
Demonstrated success in influencing colleagues and senior leaders in various departments.
Extensive leadership and line management experience, with excellent communication skills are required
Must demonstrate high integrity
Desired Experience:
Experience in the development of platform studies in multiple oncology indications with a record of successful delivery
Experience developing data and justification leading to successful Phase 3 investment decisions
Experience in the development of both small molecule and biologics, including ADCs
Key Relationships:
Internal:Early and late GPTs, Tumor strategy heads, Oncology R&D LT, Regulatory sciences, Oncology business unit.
External:Key investigators for various tumor types, Health Authorities.
Global Remit:This role operates globally, requiring interaction across numerous countries.
AstraZeneca is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees
The annual base pay for this position ranges from $303,781.60 - $455,672.40 Base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills, and experience. In addition, our positions offer a short-term incentive bonus opportunity; eligibility to participate in our equity-based long-term incentive program (salaried roles), to receive a retirement contribution (hourly roles), and commission payment eligibility (sales roles). Benefits offered included a qualified retirement program [401(k) plan]; paid vacation and holidays; paid leaves; and, health benefits including medical, prescription drug, dental, and vision coverage in accordance with the terms and conditions of the applicable plans. Additional details of participation in these benefit plans will be provided if an employee receives an offer of employment. If hired, employee will be in an “at-will position” and the Company reserves the right to modify base pay (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance, Company or individual department/team performance, and market factors.
AstraZeneca embraces diversity and equality of opportunity. We are committed to building an inclusive and diverse team representing all backgrounds, with as wide a range of perspectives as possible, and harnessing industry-leading skills. We believe that the more inclusive we are, the better our work will be. We welcome and consider applications to join our team from all qualified candidates, regardless of their characteristics. We comply with all applicable laws and regulations on non-discrimination in employment (and recruitment), as well as work authorization and employment eligibility verification requirements.
50300160
K
PRSP